Showing 1791-1800 of 3038 results for "".
- NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trialhttps://modernod.com/news/novasight-announces-successful-results-of-pivotal-amblyopia-treatment-trial/2480689/NovaSight announced positive pivotal data from its multicenter, randomized, controlled trial of CureSight, an eye-tracking based, digital treatment device for amblyopia (lazy eye). The study, which randomized 103 participants aged 4 to 9, compared the improvement in visual outcomes achieved
- FCI Ophthalmics Announces FDA Clearance of Oculid Implantable and External Eyelid Weights for the Treatment of Lagophthalmoshttps://modernod.com/news/fci-ophthalmics-announces-fda-clearance-of-oculid-implantable-and-external-eyelid-weights-for-the-treatment-of-lagophthalmos/2480641/FCI Ophthalmics announced <
- Novartis Presents Positive Results From Three Phase 3 Trials of Beovu in DMEhttps://modernod.com/news/novartis-presented-positive-results-from-three-phase-3-trials-of-beovu-in-dme/2480638/At the Angiogenesis, Exudation, and Degeneration 2022 Virtual Meeting, Novartis presented additional positive results from three phase 3 trials of Beovu in DME, including results from patients dosed at up to 16-week intervals. This was the first detailed presentation of the year 2 results&nb
- Global Eye Health Body Unites With Novartis to Strengthen Eye Health in Africahttps://modernod.com/news/global-eye-health-body-unites-with-novartis-to-strengthen-eye-health-in-africa/2480626/The International Agency for the Prevention of Blindness (IAPB) has joined together with Novartis in a partnership to strengthen eye health in Sub-Saharan Africa. The new 3-year relationship will support effective policy dialogue, planning, and implementation of eye health services in the re
- I-Med Pharma USA Partners With DryEye Rescue to Distribute Its Dry Eye Product Portfolio in the United Stateshttps://modernod.com/news/i-med-pharma-usa-partners-with-dryeye-rescue-to-distribute-its-dry-eye-product-portfolio-in-the-united-states/2480614/With the recent launch of its line of dry eye diagnostics, management, and treatment solutions into the United States, I-MED Pharma USA has partnered with DryEye Rescue of Boca Raton, Florida to distribute and market their dry eye product portfolio. DryEye Rescue will help raise awareness of
- Euclid Systems Launches MyEuclid Customer Portalhttps://modernod.com/news/euclid-systems-launches-myeuclid-customer-portal/2480579/Euclid Systems announced an initial launch of MyEuclid, a new interactive, web-based customer portal designed to help drive practice efficiency and optimize Euclid Ortho-K fits. Used on millions of eyes a
- Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Nonclinical Developmenthttps://modernod.com/news/nicox-appoints-doug-hubatsch-as-new-chief-scientific-officer-to-lead-clinical-and-nonclinical-development/2480509/Nicox SA announced the appointment of Doug Hubatsch to lead all of the company’s nonclinical and clinical development activities. As Chief Scientific Officer, Mr. Hubatsch will be responsible for setting the research and development st
- Novartis Announces Positive Year 2 Results of Phase 3 KESTREL Study of Beovu in Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-positive-results-from-year-2-of-the-phase-3-trial-of-beovu-in-diabetic-macular-edema/2480504/Novartis announced the first interpretable results from year 2 (week 100) of the phase 3 KESTREL study. KESTREL assessed the safety and efficacy of Beovu (brolucizumab) 6 mg in patients with visual impairment due to diabetic macular edema (DME). Results from year 2 confirmed the visual acuit
- Recently Approved Presbyopia Eye Drop Vuity Now Available in Pharmacieshttps://modernod.com/news/recently-approved-presbyopia-eye-drop-vuity-now-available-in-pharmacies/2480503/Allergan announced that Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the FDA to treat presbyopia, is now available by prescription in pharmacies nationwide. "We are pleased to be able to bring this first-of-its
- GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of Lumevoq Vector DNA in Contralateral Eyes After Unilateral Injectionhttps://modernod.com/news/gensight-biologics-announces-publication-of-non-human-primate-study-reporting-presence-of-lumevoq-vector-dna-in-contralateral-eyes-after-unilateral-injection/2480491/GenSight Biologics announced that the journal "Molecular Therapy – Methods and Clinical Development" has published the results of a mechanistic study demonstrating the transfer of Lumevoq vector DNA from the injected eyes to the non-injected eyes of non-human prim